Cryoport Raises 2026 Revenue Guidance Following Strong Q3 Growth
Cryoport (CYRX) reported strong third-quarter results, highlighted by a 14% year-over-year revenue increase to $50.2 million. A key driver of this growth was the Life Sciences Services segment, which saw an 18% rise and now accounts for 57% of the company's total revenue. Building on this momentum, management has raised its 2026 revenue outlook to a range of $197 million to $199 million. The company also outlined long-term profitability targets, aiming for a 55% gross margin and an adjusted EBITDA margin of 30%.
Tickers: $CYRX
Topics: life sciences services quarterly earnings revenue growth